Novo Nordisk has global metabolic leadership, an oral GLP-1 program, and a stock price below $50 after a retail-driven ...
Eli Lilly's oral GLP-1 candidate, orforglipron, won't earn approval as fast as the company expected. Meanwhile, a notable ...
Eli Lilly and Company (NYSE:LLY) is one of the best stocks to buy and hold for 20 years. On January 20, 2026, Guggenheim reduced its price target on Eli Lilly and Company (NYSE:LLY) from $1,163 to $1, ...
Zacks Investment Research on MSN
Eli Lilly (LLY) stock sinks as market gains: What you should know
In the latest trading session, Eli Lilly (LLY) closed at $1,064.29, marking a -2.12% move from the previous day. This change ...
Having stabilized following a severe downturn last summer, Viking Therapeutics has announced the completion of patient enrollment for a key clinical trial. This technical achievement marks a ...
Shares of Eli Lilly & Co. LLY slipped 1.99% to $1,063.56 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.65% to 6,966.28 and ...
On the Jan. 5, 2026, episode of The Morning Filter podcast, Morningstar Chief US Market Strategist Dave Sekera commented on what the Food and Drug Administration’s approval of Novo Nordisk’s NVO ...
Jan 7 (Reuters) - Eli Lilly (LLY.N), opens new tab will buy autoimmune drug developer Ventyx Biosciences (VTYX.O), opens new tab for $1.2 billion in cash, the companies said on Wednesday, marking the ...
Ventyx Biosciences shares rose 29% after The Wall Street Journal reported that the company is in advanced talks to be acquired by Eli Lilly. A deal for Ventyx, which specializes in developing pills ...
Eli Lilly LLY0.53%increase; green up pointing triangle is in advanced talks to acquire Ventyx Biosciences VTYX 0.22%increase; green up pointing triangle for around $1 billion, according to people ...
Eli Lilly (LLY 2.12%) is close to doing something no other pharmaceutical company has ever done: reaching $1 trillion in market value. The company briefly touched that level in November but has since ...
Novo Nordisk A/S is rated a buy, driven by FDA approval of its oral Wegovy, strong fundamentals, and attractive valuation versus Eli Lilly. Recent clinical data and first-mover advantage position ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results